Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057356 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT00057356 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 170 participants.
The verdict
NCT00057356, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.
Interventions
- DRUG placebo
- DRUG conivaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057356
The ClinicalTrials.gov registry entry for NCT00057356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00057356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057356 about?
NCT00057356 is a clinical study titled "Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure". This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.
What is the current status of trial NCT00057356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2002-11. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00057356?
The interventions under investigation include: placebo (DRUG), conivaptan (DRUG).
Who is sponsoring clinical trial NCT00057356?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.